Eric Jonasch, MD
Professor of Genitourinary Medical Oncology and VHL Clinic Director
Houston, Texas
Summary
Clinical leadership in VHL and kidney cancer: Dr. Jonasch directs MD Anderson's VHL Clinical Center and leads multidisciplinary clinical care and surveillance programs for patients with von Hippel–Lindau disease. mdanderson+1
Translational and clinical investigator: He has led investigator-initiated trials and federally funded research projects focused on renal cell carcinoma biology, biomarkers, and therapeutic resistance, including projects to develop shared VHL data/tissue resources. mdanderson
Influential academic author and guideline contributor: Jonasch is a highly cited author on kidney cancer topics, co-authoring major papers and participating in guideline panels and consensus publications shaping RCC care. google+1
Educator and mentor: As Fellowship Program Director and long-standing faculty member, he oversees trainee education in genitourinary medical oncology and contributes to academic program leadership at MD Anderson. mdanderson
Work
Education
Projects
Writing
Disease Monitoring and Treatment Patterns of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States
January 1, 2025Study describing monitoring and treatment patterns among patients with VHL-associated RCC and quantifying healthcare use and interventions in this population.
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
January 1, 2021Phase 2 clinical evaluation of belzutifan showing tumor responses in renal cell carcinoma and other VHL-associated tumors, demonstrating a new therapeutic option for VHL patients.
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
January 1, 2020Review summarizing genomic features, initiating events, and mechanisms driving progression and lethality in clear cell renal cell carcinoma (ccRCC).